Saturday 17 October 2026
Export COYA’s income statement to Excel — free account
Coya Therapeutics, Inc.
COYA Healthcare Biotechnology
Coya Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $7.9 million, up 123.6% from fiscal 2024. In the quarter to June 2026, revenue grew 49.0%, EPS grew 22.2% and free cash flow fell 27.8%, each against the same quarter a year earlier.
4.27
0.07
−1.61%
Follow COYA
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | 4.50 | 3.21 | 4.75 | 4.65 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | 4.85 | 8.00 | 10.69 | 8.29 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | 6 | 6 | 8 | 8 | 8 | ||||
| Revenue/emp, $m | — | — | — | — | — | 0.00 | 0.00 | 0.75 | 0.44 | 0.99 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | 6 | 4 | 8 | ||||
| Gross margin, % | — | — | — | — | — | 0.00 | 0.00 | 100.00 | 100.00 | 100.00 | |||||
| EBT | — | — | — | — | (1) | (5) | (12) | (7) | (16) | (21) | |||||
| EBT margin, % | — | — | — | — | 0.00 | 0.00 | 0.00 | (121.02) | (438.96) | (267.10) | |||||
| Net income | — | — | — | — | (1) | (5) | (12) | (8) | (15) | (21) | |||||
| Depreciation | — | — | — | — | — | 0 | 0 | 0 | 0 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.59 | 0.23 | 0.47 | ||||
| Earnings | — | — | — | — | (0.08) | (1.89) | (4.73) | (0.79) | (0.98) | (1.27) | |||||
| Cash flow | — | — | — | — | (0.04) | (1.51) | (2.79) | (1.10) | (0.68) | (0.64) | |||||
| Capex | — | — | — | — | 0.00 | (0.05) | (0.20) | (0.05) | 0.00 | (0.07) | |||||
| Free cash flow | — | — | — | — | (0.04) | (1.56) | (3.00) | (1.15) | (0.68) | (0.71) | |||||
| Book value | — | — | — | — | 0.86 | 1.41 | (3.24) | 3.51 | 2.60 | 2.57 | |||||
| Shares, m | — | — | — | — | 10 | 3 | 3 | 10 | 15 | 17 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | ||||
| P/S | — | — | — | — | — | — | — | 0.00 | 0.00 | 12.21 | |||||
| P/B | — | — | — | — | — | — | — | 1.99 | 2.21 | 2.26 | |||||
| EV/Sales | — | — | — | — | — | — | — | 0.00 | 0.00 | 7.95 | |||||
| EV/FCF | — | — | — | — | — | — | — | (4.21) | (6.01) | (5.31) | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | 0 | (4) | (7) | (11) | (10) | (11) | ||||
| Capex | — | — | — | — | — | 0 | (1) | (1) | 0 | (1) | |||||
| Free cash flow | — | — | — | — | 0 | (4) | (8) | (12) | (10) | (12) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | 8 | 3 | 3 | 36 | 40 | 44 | ||||
| Total debt | — | — | — | — | — | — | 13 | — | — | — | |||||
| Net debt | — | — | — | — | (9) | (4) | 7 | (33) | (38) | (47) | |||||
| Shareholders’ equity | — | — | — | — | 8 | 4 | (8) | 36 | 40 | 43 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | 0.00 | (72.25) | (185.70) | (32.17) | (34.76) | (45.02) | ||||
| ROIC | — | — | — | — | 0.00 | 0.00 | 0.00 | (164.17) | (871.34) | 0.00 | |||||
| ROE | — | — | — | — | 0.00 | 173.42 | 109.64 | (86.60) | (39.57) | (51.39) | |||||
Negative figures in brackets.
Fiscal years to Dec 2025 · latest quarter Jun 2026
Charts ten years each
Coya Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| VANI Vivani Medical, Inc. | $103.7M | — (loss-making) | — (loss-making) | −71.87% (below 0%: shrinking) | n/m | +0.39% (above 0%: growing) | 0.00% | 0.00% | Compare |
| COYA Coya Therapeutics, Inc. | $101.8M | — (loss-making) | — (loss-making) | +48.96% (above 0%: growing) | n/m | −27.79% (below 0%: shrinking) | 100.00% | (2,891.67%) | |
| UNCY Unicycive Therapeutics, Inc. | $100.0M | — (loss-making) | — (loss-making) | — | n/m | +9.77% (above 0%: growing) | 0.00% | 0.00% | Compare |
| BDTX Black Diamond Therapeutics, Inc. | $100.0M | — (loss-making) | — (loss-making) | — | n/m | +12.91% (above 0%: growing) | 100.00% | 0.00% | Compare |
| PYPD PolyPid Ltd. | $99.5M | — (loss-making) | — | — | n/m | −64.96% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| MIST Milestone Pharmaceuticals Inc. | $98.9M | — (loss-making) | — (loss-making) | −62.73% (below 0%: shrinking) | n/m | −80.81% (below 0%: shrinking) | 94.28% | (4,584.97%) | Compare |
| CBUS Cibus, Inc. | $98.6M | — (loss-making) | — (loss-making) | +6.54% (above 0%: growing) | n/m | +31.62% (above 0%: growing) | 100.00% | (1,300.30%) | Compare |
| PMVP PMV Pharmaceuticals, Inc. | $97.4M | — (loss-making) | — | — | n/m | +20.27% (above 0%: growing) | 0.00% | 0.00% | Compare |
| NRXS Neuraxis, Inc. | $97.2M | — (loss-making) | — (loss-making) | +115.71% (above 0%: growing) | n/m | +29.76% (above 0%: growing) | 85.87% | (110.16%) | Compare |
| Median of peers | $99.2M | — | — | −28.09% | — | +11.34% | 42.94% | 0.00% |
Coya Therapeutics, Inc. (COYA) key facts
- Concern: Coya Therapeutics, Inc. reported a net loss of $21.2 million, or a loss of $1.27 per share, for fiscal 2025.
- Strength: Coya Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $7.9 million, up 123.6% from fiscal 2024.
- Coya Therapeutics, Inc. (COYA) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, COYA traded at $4.27, a market capitalization of $101.8 million.
- Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 12.5× sales.
- Return on equity was −51.4% and debt-to-equity 0.00.
- Its Piotroski F-score is 3 out of 9 and its Altman Z-score is 6.40 (safe zone) for fiscal 2025.
Coya Therapeutics, Inc. (COYA) Latest News
No news at this impact. Lower the threshold for more.